Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.51 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.51 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385237 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBLCK | |
| SCHEMBL27554878 | 0.82 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL2833079 | 0.82 | SMN1; SMN2 (0.52) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL30902246 | 0.82 | SMN1; SMN2 (0.52) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Lithium Ion SCHEMBL21818896 | 0.81 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL11558582 | 0.81 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| Hydrochloric Acid SCHEMBL20269711 | 0.79 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| SCHEMBL27874136 | 0.78 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBPDE4A | |
| 4-Aminoquinazoline SCHEMBL27977310 | 0.77 | PI4KA (0.81) | PI4KAPI4K2BPI4K2API4KBLCK | |
| SCHEMBL15500822 | 0.77 | RXFP1 (0.51) | LMNAADORA3NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117751107-A | Organic pyridine-pyrazole compounds and uses thereof | 博善人工智能剑桥有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-115551354-A | Active compound combinations and fungicide compositions comprising them | 拜耳公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115551355-A | Active compound combinations and fungicide compositions comprising them | 拜耳公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115515426-A | Active compound combinations and fungicide compositions comprising them | 拜耳公司 | 2022-12-23 | — | — | CN | claimed |
| EP-3253390-B1 | AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST | MERCK SHARP & DOHME (US) | 2022-04-13 | — | — | EP | claimed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | claimed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | claimed |
| CN-109071563-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-119119035-A | RIPK1 kinase target inhibitor and preparation method and application thereof | 中山大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-117751107-A | Organic pyridine-pyrazole compounds and uses thereof | 博善人工智能剑桥有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-106986863-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-107236008-B | Quinazoline -4- amido glucosan derivative and preparation method and bioactivity | 鲁东大学 | 2019-08-06 | — | — | CN | disclosed |
| CN-107236008-B | Quinazoline -4- amido glucosan derivative and preparation method and bioactivity | 鲁东大学 | 2019-08-06 | — | — | CN | disclosed |
| EP-3119781-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | The Johns Hopkins University (US) | 2017-01-25 | — | — | EP | disclosed |
| CN-105658639-A | Alkynyl alcohols and methods of use | 豪夫迈·罗氏有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-105636958-A | Dna-pk inhibitors | VERTEX PHARMA | 2016-06-01 | — | — | CN | disclosed |
| WO-2015143293-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE, COMPOSITIONS INCLUDING SUCH COMPOUNDS, AND THEIR USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-09-24 | — | — | WO | disclosed |
| CN-104640852-A | Dna-pk inhibitors | VERTEX PHARMA | 2015-05-20 | — | — | CN | disclosed |
| CN-101171245-A | Indolylamino quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2008-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | PI4KA 3328/4885PI4K2B 4347/4885PI4K2A 4107/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | PI4KA 3328/4885PI4K2B 4347/4885PI4K2A 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.